Banks L, Matlashewski G, Pim D, Churcher M, Roberts C, Crawford L
Department of Biochemical Virology, Wellcome Research Laboatories, Kent, U.K.
J Gen Virol. 1987 Dec;68 ( Pt 12):3081-9. doi: 10.1099/0022-1317-68-12-3081.
The L1 and L2 capsid proteins encoded by human papillomavirus types 6 and 16 (HPV-6 and HPV-16) have been synthesized in bacteria. Antisera were raised against the HPV-6 L1- and L2-beta-galactosidase fusion proteins and against an HPV-16 L1 C-terminal peptide which was 14 amino acids long. The HPV-16 L1 peptide antibodies have been shown to be highly reactive with the HPV-16 L1-beta-galactosidase protein but not against the equivalent HPV-6 L1-beta-galactosidase fusion protein. The effectiveness of these antibodies was compared with commercially available antibovine papillomavirus type 1 (BPV-1) antibodies and the results demonstrated that the anti-BPV-1 antibodies reacted well against HPV-6 L1-beta-galactosidase but not against HPV-16 L1-beta-galactosidase. In addition, the L2 portion of the HPV-6 L2-beta-galactosidase fusion protein appeared particularly immunogenic, since antibodies raised against this fusion protein were predominantly reactive with the L2 moiety. The HPV-16 L1 peptide antibodies described here will be preferred reagents for the specific detection of HPV-16 capsid antigens, which may be particularly important in early diagnosis of HPV-16 infection.
人乳头瘤病毒6型和16型（HPV - 6和HPV - 16）编码的L1和L2衣壳蛋白已在细菌中合成。制备了针对HPV - 6 L1和L2 - β - 半乳糖苷酶融合蛋白以及针对一种14个氨基酸长的HPV - 16 L1 C末端肽的抗血清。已证明HPV - 16 L1肽抗体与HPV - 16 L1 - β - 半乳糖苷酶蛋白具有高度反应性，但与等效的HPV - 6 L1 - β - 半乳糖苷酶融合蛋白无反应。将这些抗体的有效性与市售的抗1型牛乳头瘤病毒（BPV - 1）抗体进行了比较，结果表明抗BPV - 1抗体与HPV - 6 L1 - β - 半乳糖苷酶反应良好，但与HPV - 16 L1 - β - 半乳糖苷酶无反应。此外，HPV - 6 L2 - β - 半乳糖苷酶融合蛋白的L2部分似乎具有特别强的免疫原性，因为针对该融合蛋白产生的抗体主要与L2部分反应。本文所述的HPV - 16 L1肽抗体将是特异性检测HPV - 16衣壳抗原的首选试剂，这在HPV - 16感染的早期诊断中可能特别重要。
